Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Remimazolam has demonstrated the potential as a valuable medication for procedural sedation and general anesthesia. However, half effective dose of remimazolam required to prevent cardiovascular response to tracheal intubation when combined with fentanyl in pediatric patients is still unknown.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| remimazolam | Experimental | Remimazolam is given for anesthesia induction. The initial dosage is 0.4mg/kg, and the interval dosage is 0.02mg/kg. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Remimazolam | Drug | remimazolam is given intravenously |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| half effective dose for intubation | half effective dose of remimazolam required to prevent cardiovascular response to tracheal intubation when combined with fentanyl | from injection of remimazolam to completed tracheal intubation, at an average of 5 minutes |
| cardiovascular response to tracheal intubation | cardiovascular response is defined as increase of blood pressure or heart rate higher than 20% of the baseline value by 3 minutes after intubation | from injection of remimazolam to 3 minutes after tracheal intubation, at an average of 8 minutes |
| Measure | Description | Time Frame |
|---|---|---|
| the time to loss of consciousness | from injection of remimazolam to loss of consciousness, at an average of 3 minutes | |
| incidence of adverse events | adverse events include bradycardia, hypotension, hypoxemia, and injection pain |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36843931 | Background | Fang YB, Wang CY, Gao YQ, Cai YH, Chen J, Zhang XL, Dong LQ, Shang-Guan WN, Liu HC. The safety and efficacy of remimazolam tosylate for induction and maintenance of general anesthesia in pediatric patients undergoing elective surgery: Study protocol for a multicenter, randomized, single-blind, positive-controlled clinical trial. Front Pharmacol. 2023 Feb 10;14:1090608. doi: 10.3389/fphar.2023.1090608. eCollection 2023. | |
| 37373624 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C522201 | remimazolam |
Not provided
Not provided
Not provided
The initial dose is 0.4mg/kg and the dose interval is 0.2mg/kg
Not provided
Not provided
Not provided
Not provided
| from injection of remimazolam to loss of consciousness, at an average of 3 minutes |
| Background |
| Kimoto Y, Hirano T, Kuratani N, Cavanaugh D, Mason KP. Remimazolam as an Adjunct to General Anesthesia in Children: Adverse Events and Outcomes in a Large Cohort of 418 Cases. J Clin Med. 2023 Jun 8;12(12):3930. doi: 10.3390/jcm12123930. |